… a phase I study of erlotinib in Japanese patients with solid tumors, 15 which showed erlotinib
to be well tolerated at a dose of 150 mg/d, as well as a phase II study of erlotinib in NSCLC …

… Firstly, our study enrolled only Japanese patients, therefore we await the results of other …
patients treated with the combination of erlotinib plus bevacizumab in countries other than Japan…

… designed to investigate erlotinib for the first-line treatment of Japanese patients with EGFR
… -line erlotinib monotherapy had a favorable efficacy and safety profile in Japanese patients …

… by the Japanese government, and few agents are available in the salvage setting in Japan.
… a phase II trial of erlotinib monotherapy in Japanese patients with relapsed NSCLC who did …

… The frequency of skin-related adverse events in the current study was comparable to the
frequency of skin disorders reported in a large-scale erlotinib-treated Japanese cohort [24]. In …

… of erlotinib-naïve subjects, erlotinib is recommended as third-line therapy. However, the
efficacy of erlotinib as third-line chemotherapy for Japanese patients … of erlotinib in patients with …

… (NSCLC) had been focused on monotherapy of gefitinib, erlotinib, or afatinib. Combinations
… combination with erlotinib (150 mg daily) plus bevacizumab (15 mg/kg iv q3w) or erlotinib (…

… Since the steady-state plasma trough concentration of erlotinib is approximately … erlotinib
may be as effective as full-dose therapy, with less toxicity and cost. Methods: Eligible patients …

… to the clinical efficacy of erlotinib in patients with NSCLC (14-… and safety of erlotinib in
Japanese patients with relapsed or … safety of erlotinib monotherapy for Japanese patients with …

… Japanese treatment guidelines recommend gefitinib or erlotinib monotherapy for patients
with EGFR-mutated NSCLC. A recent Japanese Phase III trial directly comparing gefitinib and …